Acceleron Reports Third Quarter 2018 Operating and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acceleron Pharma (XLRN) Tops Q3 EPS by 3c, Revenues Miss
October 30, 2018 4:12 PM EDTAcceleron Pharma (NASDAQ: XLRN) reported Q3 EPS of ($0.63), $0.03 better than the analyst estimate of ($0.66). Revenue for the quarter came in at $3.26 million versus the consensus estimate of $3.9 million.
2018 is proving to be a pivotal year for Acceleron, and with several key milestones approaching, we... More
